Otsuka reported that Voyxact (a monoclonal antibody for IgA nephropathy) slowed kidney function decline after one year, but the benefit landed below expectations in a Phase 3 study. eGFR-based outcomes showed annualized function loss of 3.0 points in the active arm versus 7.6 points with placebo. The report adds a regulatory tension point: even when primary efficacy signals exist, commercial positioning can shift quickly if the magnitude of effect is viewed as insufficient against the evolving standard of care. Analysts and clinicians will now pressure-test how the data compare with competing therapies targeting IgA nephropathy. For sponsors, the episode highlights the importance of effect-size context—not just statistical significance—when aiming for full approval.